Nektar reports updated response data from Phase Ib of NKTR-214 plus Opdivo

Nektar Therapeutics (NASDAQ:NKTR) President and CEO Howard Robin said on March 2 that two additional renal cell carcinoma (RCC) patients who previously achieved stable disease have converted to responders in the Phase Ib portion of the Phase Ib/II